Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Majority of EOLOA Applicants Choose Death

By HospiMedica International staff writers
Posted on 08 Jan 2018
A new study shows that three quarters of terminally ill adults in California qualified to receive End of Life Option Act (EOLOA) drugs ingest them and die.

In a new research letter, investigators at Kaiser Permanente School of Medicine (Pasadena, CA, USA) and Kaiser Permanente Southern California (Pasadena, USA) described how Kaiser Permanente dealt with the first year of implementation of EOLOA, providing outcomes and characteristics of 379 individuals who initiated the EOLOA process. More...
The most common reasons cited for pursuing EOLOA were not wanting to suffer and no longer being able to participate in activities that made life enjoyable.

Of the 379 patients initiated an inquiry through June 30, 2017, 176 were deemed eligible, with 55% of the patients suffering impairment in activities of daily living and receiving palliative care, or were staying at a hospice at the time of their inquiry. Most of the patients suffered from cancer, and in the previous 12 months had received care mainly from specialists. In all, 74% of the patients who received the EOLOA drugs ingested them and died within a median of nine days after receiving the prescription. The study research letter was published on December 26, 2017, in JAMA Internal Medicine.

“The California End of Life Option Act, which took effect on June 9, 2016, allows qualified adults diagnosed with a terminal disease to request aid-in-dying drugs from their physician,” concluded lead author Huong Nguyen, PhD, and colleagues. “Patients' end-of-life concerns appear difficult to palliate, with the most common cited reasons for pursuing EOLOA being existential suffering, inability to enjoy life, and loss of autonomy.”

California is the fifth state in the United States to enact an aid-in-dying law. To be eligible, an individual must be an adult, a California resident, have a diagnosis from a primary physician of an incurable and irreversible disease which will, within reasonable medical judgment, result in death within six months. Petitioners must be confirmed to be able to make medical decisions for themselves, voluntarily request the aid-in-dying drug without influence from others, and be able to self-administer the drug. Requests must be made solely and directly by the patient to the attending physician, and cannot be made through a power of attorney, health care agent, or any other legally recognized health care decision maker.

Related Links:
Kaiser Permanente School of Medicine
Kaiser Permanente Southern California


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
PACS Workstation
PaxeraView PRO
OR Table Accessory
Angular Accessory Rail
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.